Haemostasis Research Unit, Department of Haematology, University College London, London, UK.
Br J Haematol. 2010 Apr;149(2):195-208. doi: 10.1111/j.1365-2141.2010.08094.x. Epub 2010 Feb 8.
The widespread use of central neuraxial block (CNB) and the prevalence of anticoagulation for different indications have led to an inevitable overlap between the two. The most serious complication of CNB in anticoagulated patients is the risk of spinal/epidural haematoma. Performing CNB in these patients is a complex decision that should take into account the twin risks of bleeding and venous/arterial thrombosis if anticoagulation therapies were to be stopped. Various guidelines have been issued to achieve normal haemostasis and thus allow safe administration of CNB. However, the evidence base for many such recommendations is weak, relying mainly on case reports, small studies and pharmacokinetics of the drugs. Given these limitations it is crucial to fully assess individual risk factors and understand anticoagulant pharmacokinetics in order to appropriately set time intervals for catheter insertion/removal. This paper will review traditional and newer anticoagulation/antiplatelet therapies with a view to improving the management of anticoagulated patients undergoing CNB.
广泛使用中枢神经轴阻滞(CNB)和不同适应症的抗凝治疗导致两者之间不可避免地重叠。抗凝治疗患者行 CNB 最严重的并发症是脊髓/硬膜外血肿的风险。在这些患者中进行 CNB 是一个复杂的决策,应考虑到如果停止抗凝治疗,出血和静脉/动脉血栓形成的双重风险。已经发布了各种指南来实现正常止血,从而允许安全进行 CNB。然而,许多此类建议的证据基础薄弱,主要依赖于病例报告、小型研究和药物的药代动力学。鉴于这些局限性,充分评估个体风险因素并了解抗凝药的药代动力学对于适当地设置导管插入/拔出的时间间隔至关重要。本文将回顾传统和新型抗凝/抗血小板治疗,以期改善接受 CNB 的抗凝治疗患者的管理。